New Regulatory Affairs Agency To Target Price Controls

BMI View: While recent regulatory developments give reason for us maintain our favourable view of Bolivia's drug approvals system and registration process, we believe the country's small market size and business environment difficulties will only appeal to risk-averse investors, keeping the country as a secondary choice for the majority of drugmakers looking to penetrate Latin American's more lucrative markets.

To read the full article, please choose one of the following options: